Novozymes A/S
Novozymes A/S (NVZMF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
nvzmf · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Novozymes A/S (NVZMF) measures how much investors pay for each dollar of the company's trailing earnings. NVZMF's current PE ratio of 39.35x is calculated by dividing its stock price of $56.36 by its TTM earnings per share of $1.28. −79.9% discount vs 5Y avg 195.9x
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 20 fiscal years · Front-end computedMinQ1 · 25%30.1x
MedianQ3 · 75%590.2x
Max
At 39.35x, NVZMF's current P/E is higher than in 85% of its annual fiscal year readings over the past 20 years — historically elevated.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Chemicals - Specialty · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Novozymes A/SYou NVZMF | $26.3B | 39.35x | +156.7% | $1.28 |
 Asia Carbon Industries, Inc. ACRB | $0M | 3.63x | -76.3% | $0.12 |
 L'Air Liquide S.A. AIQUF | $133.5B | 26.21x | +70.9% | $6.10 |
 Akzo Nobel N.V. AKZOF | $11.4B | 14.91x | -2.7% | $3.71 |
 Akzo Nobel N.V. AKZOY | $33.9B | 16.57x | +8.1% | $1.19 |
 Air Products and Chemicals, Inc. APD | $62.4B | N/A | — | -$1.77 |
 Avoca LLC AVOA | $12M | N/A | — | — |
Industry Average 4 peers with valid PE | — | 15.33x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | 282.18x | $1.41 | -52.2% | |
2024-12-31 FY2024 | 590.19x | $0.67 | +1683.2% | |
2023-12-31 FY2023 | 33.10x | $10.89 | +24.8% | |
2022-12-31 FY2022 | 26.52x | $13.19 | -44.2% | |
2021-12-31 FY2021 | 47.53x | $11.32 | +37.4% | |
2020-12-31 FY2020 | 34.58x | $10.07 | +17.9% | |
2019-12-31 FY2019 | 29.33x | $11.06 | +11.3% | |
2018-12-31 FY2018 | 26.36x | $11.11 | -20.9% | |
2017-12-31 FY2017 | 33.31x | $10.56 | +39.2% | |
2016-12-31 FY2016 | 23.93x | $10.15 | -32.9% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Novozymes A/S (NVZMF) measures how much investors pay for each dollar of the company's trailing earnings. NVZMF's current PE ratio of 39.35x is calculated by dividing its stock price of $56.36 by its TTM earnings per share of $1.28.
Frequently asked questions
NVZMF pe ratio · 6 questionsNVZMF's current PE ratio is 39.35x as of 2026-06-09, based on a stock price of $56.36 and TTM EPS of $1.28. Data sourced from Financial Modeling Prep via NVZMF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Novozymes A/S SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09